Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

AstraZeneca plc (ADR) (AZN) CEO Pascal Soriot Banking On Accelerated Pipeline For Rapid Development

AstraZeneca plc (ADR) (NYSE:AZN) was considered somewhat of a dying flame two years ago, according to its CEO Pascal Soriot, but now the company is set for high paced development in the pharmaceutical industry with several essential new drugs coming up.

AstraZeneca plc (ADR) (NYSE:AZN)

In an interview on CNBC, Soriot highlighted that the new and improved AstraZeneca plc (ADR) (NYSE:AZN)’s success is based on two important factors. First and foremost is the accelerated pipeline which enables the company to get its drugs past the testing phases and to the consumers much faster. As an example, he mentioned the new lung cancer medicine that AstraZeneca plc (ADR) (NYSE:AZN) has pushed to the shelves in record time.

“[…] What we have also done over the last two years is that we have accelerated some of the internal projects that were in early development and we are moving them into late stage development. An example of this is 9291. It is a code name for our new product for lung cancer. This is really meeting a key unmet need in lung cancer patients. This product will have moved from phase 1 to filing with FDA and EMa in Europe in less than two and a half years. It probably will be the fastest development ever in the industry, so we have accelerated internal pipelines,” informed Soriot.

The second pillar that is supporting the additional pace of new drugs for AstraZeneca plc (ADR) (NYSE:AZN) is the money that the company is pumping into the early development phase of these drugs. There are two ways that such a boost could occur for companies operating in the pharmaceutical sector. Either through mergers and acquisitions whereby a large concern acquires a smaller company with promising results pertaining to upcoming drugs, or what AstraZeneca plc (ADR) (NYSE:AZN) has done, that is shower its own R&D department with more resources.

” […] The final thing that we have done is that we have rebuilt our early research and early development engine, if you want, and now this is producing results and  those projects are moving through the pipeline […],” said Soriot.

Warren Buffett and BillionairesFree Report: Warren Buffett and 12 Billionaires Are Crazy About These 7 Stocks

Let Warren Buffett, David Einhorn, George Soros, and David Tepper WORK FOR YOU. If you want to beat the low cost index funds by an average of 6 percentage points per year look no further than Warren Buffett’s stock picks. That’s the margin Buffett’s stock picks outperformed the market since 2008. In this free report, Insider Monkey’s market beating research team identified 7 stocks Warren Buffett and 12 other billionaires are crazy about. CLICK HERE NOW for all the details.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!